What is the long-term trend for Arbutus Biopharma Corporation's unrealized gains on investments?

Over 2 years (2020 to 2025), Arbutus Biopharma Corporation's unrealized gains on investments has grown at a 140.8% compound annual growth rate (CAGR), from $15K to $87K.

Arbutus Biopharma Corporation ABUS Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Vir Biotechnology, Inc.VIR

——

Ligand PharmaceuticalsLGND

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Balance sheet

See full

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Cash flow

See full

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Valuation

See full

Market cap$871.14M+32.6%

Enterprise value$848.07M+36.6%

P/E5.4×—

P/S4.6×-98.0×

Profitability

See full

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Returns & leverage

See full

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arbutus Biopharma Corporation's unrealized gains on investments?: Arbutus Biopharma Corporation (ABUS) reported unrealized gains on investments of $13K in Q1 2026.
How has Arbutus Biopharma Corporation's unrealized gains on investments changed year-over-year?: Arbutus Biopharma Corporation's unrealized gains on investments decreased by 48.0% year-over-year, from $25K to $13K.
What is the long-term trend for Arbutus Biopharma Corporation's unrealized gains on investments?: Over 2 years (2020 to 2025), Arbutus Biopharma Corporation's unrealized gains on investments has grown at a 140.8% compound annual growth rate (CAGR), from $15K to $87K.